| Autor: |
Olesen, Tina Bech, Andersen, Ina Trolle, Ording, Anne Gulbech, Ehrenstein, Vera, Seesaghur, Anouchka, Helleberg, Carsten, Silkjær, Trine, Hernandez, Rohini K., Niepel, Daniela, Abildgaard, Niels |
| Předmět: |
|
| Zdroj: |
Supportive Care in Cancer; Aug2021, Vol. 29 Issue 8, p4501-4511, 11p |
| Abstrakt: |
Purpose: To describe use of bisphosphonates in newly diagnosed multiple myeloma patients in Denmark. Methods: Using data from the Danish National Multiple Myeloma Registry, we conducted a population-based cohort study. Among patients newly diagnosed with multiple myeloma from 2005 to 2015, we examined use of bisphosphonates at first- and at progression/second-line anti-myeloma treatment overall, by patient characteristics, and myeloma complications. Results: Of 2947 patients starting first-line anti-myeloma treatment, 2207 patients (74.9%) received bisphosphonates. During a median follow-up of 27.6 (quartiles, 10.6–52.5) months, disease progression post-first-line treatment was recorded in 1546 patients, of whom 1065 (68.9%) were treated with bisphosphonates. Altogether, 80.9% of patients with and 37.6% of patients without myeloma bone disease were treated with bisphosphonates at first line and 73.0% and 42.7%, respectively, at progression/second line. Moreover, the proportion of patients treated with bisphosphonates decreased with increasing severity of renal impairment at first and at progression/second-line treatment. Conclusion: The proportion of patients treated with bisphosphonates as part of first- and second-line anti-myeloma treatment increased with presence of myeloma bone disease and decreased by presence and severity of renal impairment. Overall, 25% of newly diagnosed multiple myeloma patients had no record of bisphosphonate treatment, potentially indicating an unmet need. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink